Performance assessment of 11 commercial serological tests for SARS-CoV-2 on hospitalised COVID-19 patients.

ABSTRACT:

Background

Commercial availability of serological tests to evaluate immunoglobulins (Ig) targeting severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has grown exponentially since the start of the coronavirus disease 2019 (COVID-19) outbreak. Thorough validation of these tests is important before use as epidemiological tools to infer seroprevalence in specific populations and as diagnostic tools to complement molecular approaches (e.g., quantitative reverse transcription-polymerase chain reaction).

Methods

Commercial serological tests from 11 suppliers were assayed side-by-side using 126 samples from SARS-CoV-2-infected inpatients and 36 from healthy and HIV-infected individuals.

Results

The majority of the tests assayed have >95% specificity. For the sensit

SUBMITTER: Serre-Miranda C 

PROVIDER: S-EPMC7817432 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature